Uncategorized
From Microbes to Materials—ZymoChem’s Vision for a Plastic-Free FutureZymoChem’s Vision for a Plastic-Free Future
From Microbes to Materials—ZymoChem’s Vision for a Plastic-Free FutureZymoChem’s Vision for a Plastic-Free Future
In this episode of the Podcast, SynBioBeta founder and CEO, John Cumbers, speaks with Harshal Chokhawala, co-founder and CEO of ZymoChem, about how the company is reengineering the foundations of materials science using microbial fermentation. Harshal discusses his scientific journey from organic chemistry to building a carbon-conserving biotech platform capable of producing bio-based adipic acid, a key component in nylon 66. Their recent partnership with lululemon aims to bring sustainable, high-performance textiles to market.
The conversation also touches on ZymoChem’s second major innovation: a biodegradable superabsorbent polymer for use in diapers—a response to the overwhelming waste generated by the hygiene industry. Harshal explains their BAYSE platform, the technology powering these innovations, and how they’re scaling up production to meet market demand.
The discussion closes with thoughts on scaling biomanufacturing, policy support, and the broader bioeconomy opportunity in the U.S.
Uncategorized
Replimune melanoma drug wins support of FDA panel

The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.

The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.
Uncategorized
Alnylam plunges as earnings deliver ‘one-two punch’

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.
Uncategorized
Capricor’s data clash and a fugitive in the C-suite
Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
-
Fierce Biotech4 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Endpoints News4 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized4 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State